Attenuation of Innate Immunity by Andrographolide Derivatives Through NF-κB Signaling Pathway
Affiliations
Andrographolide derivatives or analogs exhibit potent anti-inflammatory effects in several disease models through NF-κB activity. In this study, we synthesized different andrographolide derivatives and investigated their effects on the toll-like receptor (TLR)-induced production of pro-inflammatory cytokines. Among these compounds, 3b, 5a, and 5b inhibited both TNF-α/NF-κB and TLR4/NF-κB signaling pathways. Treatment with compounds 3b, 5a, and 5b and their structural analogs, 3a and 6b, suppressed the expression of pro-inflammatory cytokines upon the activation of TLR3 and TLR4 ligands. Compounds 3b and 5a, but not 3a, 5b, or 6b, inhibited the nuclear translocation of the NF-κB p65 subunit. Treatment with compounds 3b, 5a, 3a, 5b, and 6b attenuated the phosphorylation of p65 and IκBα. Compounds 6b suppressed the expression of the NF-κB p65 subunit. However, these compounds, except for 5b, did not affect the TLR9-induced NF-κB-independent production of the pro-inflammatory cytokines, TNF-α, and IFN-β. Compound 3b potentially protected mice from LPS-induced acute pulmonary inflammation through the inhibition of p65 phosphorylation and the decrease of serum pro-inflammatory cytokines and chemokine. Our study revealed a functional structure-activity relationship between andrographolide derivatives and innate immunity. We identified compound 3b as a potent immune suppressive agent with the potential to protect acute pulmonary infection.
Kongsomros S, Boonyarattanasoonthorn T, Phongphaew W, Kasorndorkbua C, Sunyakumthorn P, Im-Erbsin R J Tradit Complement Med. 2025; 14(6):598-610.
PMID: 39850600 PMC: 11752117. DOI: 10.1016/j.jtcme.2024.05.004.
Lugtmeijer C, Bowtell J, OLeary M Nutrients. 2024; 16(14).
PMID: 39064738 PMC: 11279956. DOI: 10.3390/nu16142291.
Mohammed M Front Pharmacol. 2023; 14:1111329.
PMID: 37124230 PMC: 10134036. DOI: 10.3389/fphar.2023.1111329.
Andrographolide, a natural anti-inflammatory agent: An Update.
Li X, Yuan W, Wu J, Zhen J, Sun Q, Yu M Front Pharmacol. 2022; 13:920435.
PMID: 36238575 PMC: 9551308. DOI: 10.3389/fphar.2022.920435.
Blevins H, Xu Y, Biby S, Zhang S Front Aging Neurosci. 2022; 14:879021.
PMID: 35754962 PMC: 9226403. DOI: 10.3389/fnagi.2022.879021.